- Trials with a EudraCT protocol (380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
380 result(s) found for: Bladder Cancer AND Cancer.
Displaying page 6 of 19.
| EudraCT Number: 2018-003520-37 | Sponsor Protocol Number: RG_18-220 | Start Date*: 2020-02-07 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer | |||||||||||||
| Medical condition: Muscle invasive bladder cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005565-13 | Sponsor Protocol Number: 17000139BLC2002 | Start Date*: 2021-10-26 | ||||||||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
| Full Title: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are... | ||||||||||||||||||||||||||||
| Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-002206-20 | Sponsor Protocol Number: MK-3475-052 | Start Date*: 2014-12-22 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer | |||||||||||||
| Medical condition: advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DK (Completed) IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001679-36 | Sponsor Protocol Number: ML41007 | Start Date*: 2019-09-26 | |||||||||||
| Sponsor Name:Aarhus University | |||||||||||||
| Full Title: Treatment Of Metastic Bladder cancer at the time Of biochemical reLApse following radical cystectomy | |||||||||||||
| Medical condition: Biochemical relapse in patients who have undergone radical cystectomy because of muscle-invasive transitional cell carcinoma of the urinary bladder | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000235-51 | Sponsor Protocol Number: ANZUP1301 | Start Date*: 2020-11-11 |
| Sponsor Name:Nottingham University Hospitals NHS Trust | ||
| Full Title: BCG+MM Trial Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase 3 trial | ||
| Medical condition: High grade non muscle invasive bladder cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000222-24 | Sponsor Protocol Number: CYC140-101 | Start Date*: 2022-06-07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Cyclacel Pharmaceuticals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: ADVANCED SOLID TUMORS AND LYMPHOMA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-000782-36 | Sponsor Protocol Number: AGO/2013/002 | Start Date*: 2013-08-13 | |||||||||||
| Sponsor Name:Ghent University Hospital | |||||||||||||
| Full Title: Effect of TachoSil® on incidence of symptomatic and radiographic lymphoceles after extended pelvic lymph node dissection in prostate and bladder cancer. | |||||||||||||
| Medical condition: Patients with prostate cancer or bladder cancer, undergoing transperitoneal pelvic lymph node dissection. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001527-39 | Sponsor Protocol Number: SGN22E-002 | Start Date*: 2021-02-16 | ||||||||||||||||||||||||||
| Sponsor Name:Seagen Inc. | ||||||||||||||||||||||||||||
| Full Title: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer | ||||||||||||||||||||||||||||
| Medical condition: Urothelial cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) IT (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-001225-33 | Sponsor Protocol Number: UC-0105/1401 | Start Date*: 2014-07-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-002646-16 | Sponsor Protocol Number: 17000139BLC2001 | Start Date*: 2021-04-26 | ||||||||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
| Full Title: Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cance... | ||||||||||||||||||||||||||||
| Medical condition: Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2013-001699-39 | Sponsor Protocol Number: HER117158 | Start Date*: 2015-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research Development Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with advanced HER3-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-003680-11 | Sponsor Protocol Number: PRESURGY/01/2015 | Start Date*: 2015-12-15 |
| Sponsor Name:PRESURGY S.L. | ||
| Full Title: Impact of the mitomicin-C (MMC) preoperative administration in patients with primary urothelial non-muscle invasive (TVNMI) bladder cancer using electromotive instillation (EMDA). Prospective rando... | ||
| Medical condition: Impact of the mitomicin-C (MMC) preoperative administration in patients with primary urothelial non-muscle invasive bladder cancer (TVNMI) using electromotive instillation (EMDA). Prospective rando... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-000850-78 | Sponsor Protocol Number: IB2019-01 | Start Date*: 2021-01-20 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||||||||||||
| Full Title: Atezolizumab combined with BDB001 and immunogenic radiotherapy in participants with advanced solid tumors. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: - pancreatic cancer - virus-associated tumors - non-small cell lung cancer - soft-tissue sarcoma - bladder cancer - Triple negative breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-000047-26 | Sponsor Protocol Number: AN05-7301 | Start Date*: 2006-03-10 |
| Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
| Full Title: A randomized controlled trial of caudal epidural or intravenous fentanyl on the post-operative analgesia requirements after transurethral endoscopic resection of prostate, bladder neck or bladder t... | ||
| Medical condition: Bladder spasm following endoscopic resection for: Bladder tumour Prostate hypertrophy Prostate cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-002417-35 | Sponsor Protocol Number: NUCOGI-VINGEM | Start Date*: 2013-09-10 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Department of Oncology, Karolinska University Hospital | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin /gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Locally advanced or Metastatic urothelial carcinoma | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: SE (Completed) DK (Completed) FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-000968-16 | Sponsor Protocol Number: F1J-FR-HAAB | Start Date*: 2008-11-18 | |||||||||||
| Sponsor Name:CeRePP | |||||||||||||
| Full Title: EFFICACY OF DULOXETINE IN THE TREATMENT OF URINARY INCONTINENCEAFTER PROSTATECTOMIE DUE TO CANCER | |||||||||||||
| Medical condition: We want to evaluate the effect of Duloxetine 40mg BID (80mg daily dose) on the number of urinary incontinence episodes as shown on a 74 days bladder diary, compared to placebo for male which had a... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001359-36 | Sponsor Protocol Number: CA223-001 | Start Date*: 2016-07-26 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refracto... | |||||||||||||
| Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) FR (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-004895-21 | Sponsor Protocol Number: NEO-BLADE | Start Date*: 2014-01-17 | |||||||||||
| Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
| Full Title: Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr | |||||||||||||
| Medical condition: Muscle invasive bladder cancer - localised muscle invasive carcinoma (T2-T4a N0 M0) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000615-23 | Sponsor Protocol Number: UC-IMM-2101 | Start Date*: 2021-06-17 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K ... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-001833-14 | Sponsor Protocol Number: EAURF2018-02 | Start Date*: 2020-12-04 | |||||||||||
| Sponsor Name:EAU Research Foundation | |||||||||||||
| Full Title: Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who hav... | |||||||||||||
| Medical condition: pT3-4 and/or pN1-3 urothelial carcinoma (UC) of the urinary bladder or upper urinary tract after radical cystectomy /radical nephroureterectomy previously treated with at least three cycles of ne... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
